An attractive cancer target is going to be in the hot seat at an FDA advisory committee on April 21.
The FDA’s oncologic drugs advisory committee, or ODAC, will specifically discuss a particular class of cancer drugs, known as phosphatidylinositol-3-kinase, or PI3K, inhibitors, that are currently under development in patients...
